Elite in Neuroblastoma

Ruth L. Ladenstein

St. Anna Children's Hospital, 
Vienna, AT 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Neuroblastoma
St. Anna Children's Hospital, 
Vienna, AT 
OverviewLocationsClinical Research

Overview

Ruth Ladenstein practices in Vienna, Austria. Ms. Ladenstein is rated as an Elite expert by MediFind in the treatment of Neuroblastoma. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Bone Marrow Transplant, and Osteotomy.

Her clinical research consists of co-authoring 147 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 67 articles and participated in 4 clinical trials in the study of Neuroblastoma.

Gender
Female

Locations

St. Anna Children's Hospital, Vienna, 1090, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
Enrollment Status: Recruiting
Publish Date: February 07, 2024
Intervention Type: Other
Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome
Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drugs: Dexamethasone Acetate, Dexamethasone and Cyclophosphamide, Dexamethasone and Rituximab
Study Phase: Phase 3
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Temozolomide, Irinotecan, Topotecan, Dinutuximab Beta, Cyclophosphamide
Study Phase: Phase 2
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Enrollment Status: Completed
Publish Date: December 08, 2023
Intervention Type: Drug
Study Drug: ch14.18/CHO
Study Phase: Phase 2
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
Enrollment Status: Unknown
Publish Date: July 14, 2020
Intervention Type: Drug
Study Drugs: ch14.18/CHO, Aldesleukin, Isotretinoin
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

147 Total Publications

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.
Journal: Cancers
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ladenstein's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile